Vertex Pharmaceuticals announced that the European Commission has granted approval for the label extension of Orkambi for the treatment of children with cystic fibrosis, or CF, ages one to less than two years old who have two copies of the F508del mutation in the cystic fibrosis transmembrane conductance regulator, or CFTR, gene, the most common form of the disease.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on VRTX:
- Vertex Pharmaceuticals price target raised to $340 from $305 at Morgan Stanley
- Sigilon Therapeutics downgraded to Neutral from Buy at BTIG
- Vertex Pharmaceuticals price target raised to $360 from $350 at TD Cowen
- Vertex Pharmaceuticals’ VX-880 showed treatment benefit, says BMO Capital
- Vertex Pharmaceuticals price target raised to $379 from $375 at Evercore ISI
